Trial Profile
An Open Labeled, Noncomparative, Phase I Study to Evaluate the Safety and Tolerability of a Fully Liquid Pentavalent DTwP-Hib-IPV Vaccine (Easyfourpol) of Panacea Biotec Ltd. Administered in Healthy Children 15- 18 Months of age.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Aug 2016
Price :
$35
*
At a glance
- Drugs Hib-DTP-poliovirus vaccine (Primary)
- Indications Diphtheria; Influenza B virus infections; Pertussis; Poliomyelitis; Tetanus
- Focus Adverse reactions
- Sponsors Panacea Biotec
- 23 Dec 2010 Status changed from recruiting to completed as reported by Clinical Trials Registry - India record.
- 13 Sep 2010 New trial record